SCHEMBL3828641

SCHEMBL3828641

Cc1c(C#N)cnc(Br)c1Br

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
KDR P35968 2/20 0.35
ABL1 P00519 1/20 0.35
CSNK1A1 P48729 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
HTT P42858 1/20 0.33
LRRK2 Q5S007 1/20 0.33
EGFR P00533 3/20 0.32
ERBB2 P04626 3/20 0.32
CHRNB2 P17787 2/20 0.31
CHRNB4 P30926 2/20 0.31
CHRNA3 P32297 2/20 0.31
CHRNA4 P43681 2/20 0.31
MAPK1 P28482 1/20 0.31
EGLN2 Q96KS0 1/20 0.31
PLK4 O00444 1/20 0.30
CHEK1 O14757 1/20 0.30
AURKA O14965 1/20 0.30
CHUK O15111 1/20 0.30
ROCK2 O75116 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2981053 0.84 CSNK1A1 (0.39) TSHRKDRABL1CSNK1A1CLK4
SCHEMBL18299745 0.83 TSHR (0.35) TSHRKDRABL1CSNK1A1CLK4
SCHEMBL20489454 0.82 HTT (0.44) TSHRKDRABL1CSNK1A1CLK4
SCHEMBL7264178 0.75 CCR1 (0.41)
SCHEMBL19009020 0.71 TSHR (0.39) TSHRKDRCSNK1A1CLK4LRRK2
SCHEMBL29741000 0.71 TSHR (0.39) TSHRKDRCSNK1A1CLK4LRRK2
SCHEMBL11184837 0.71 CHRNB2 (0.40) KDRABL1HTTCHRNB2CHRNB4
SCHEMBL19741191 0.71 CSNK1A1 (0.41) TSHRCSNK1A1CLK4HTTLRRK2
SCHEMBL3826142 0.71 S1PR2 (0.37) TSHRKDRABL1CSNK1A1CLK4
SCHEMBL11192626 0.71 CCR1 (0.34) HTTDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999110-B1 PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES UCB PHARMA SA (BE) 2009-09-16 EP disclosed
US-20090221828-A1 Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives UCB PHARMA, S.A. (BE) 2009-09-03 US disclosed
EP-1999110-A2 PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES UCB Pharma, S.A. (BE) 2008-12-10 EP disclosed
WO-2007107345-A2 PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES UCB PHARMA, S.A. (BE) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221828-A1 Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives NPM1, XPO4, BRD7 TSHR 2348/4885KDR 3230/4885ABL1 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.